Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

NCT05473910 is registered in ClinicalTrials.gov with TScan Therapeutics, Inc. as lead sponsor.

NCT NCT05473910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05473910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
Lead sponsor
TScan Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 1, 2022
Completion date
June 30, 2028
Enrollment
310 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds